Article | Published:

Isolation of amniotic stem cell lines with potential for therapy

Nature Biotechnology volume 25, pages 100106 (2007) | Download Citation

Subjects

Abstract

Stem cells capable of differentiating to multiple lineages may be valuable for therapy. We report the isolation of human and rodent amniotic fluid–derived stem (AFS) cells that express embryonic and adult stem cell markers. Undifferentiated AFS cells expand extensively without feeders, double in 36 h and are not tumorigenic. Lines maintained for over 250 population doublings retained long telomeres and a normal karyotype. AFS cells are broadly multipotent. Clonal human lines verified by retroviral marking were induced to differentiate into cell types representing each embryonic germ layer, including cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. Examples of differentiated cells derived from human AFS cells and displaying specialized functions include neuronal lineage cells secreting the neurotransmitter L-glutamate or expressing G-protein-gated inwardly rectifying potassium channels, hepatic lineage cells producing urea, and osteogenic lineage cells forming tissue-engineered bone.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Origin of cells in human amniotic fluid cultures: ultrastructural features. Lab. Invest. 39, 106–109 (1978).

  2. 2.

    et al. Characterization of rapidly adhering amniotic fluid cells by combined immunofluorescence and phagocytosis assays. Am. J. Hum. Genet. 45, 786–792 (1989).

  3. 3.

    et al. Human fetal stem cell isolation from amniotic fluid. In American Academy of Pediatrics National Conference, p. 210–211, (San Francisco, 2001).

  4. 4.

    et al. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 102, 1548–1549 (2003).

  5. 5.

    , , & Isolation of human multipotent mesenchymal stem cells from second-trimester amniotic fluid using a novel two-stage culture protocol. Hum. Reprod. 19, 1450–1456 (2004).

  6. 6.

    et al. Neurogenic cells in human amniotic fluid. Am. J. Obstet. Gynecol. 191, 309–314 (2004).

  7. 7.

    & Widespread engraftment of neural progenitor and stem-like cells throughout the mouse brain. Transplant. Proc. 29, 845–847 (1997).

  8. 8.

    et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63, 213–224 (1990).

  9. 9.

    , , , & The monoclonal antibody SH-2, raised against human mesenchymal stem cells, recognizes an epitope on endoglin (CD105). Biochem. Biophys. Res. Commun. 265, 134–139 (1999).

  10. 10.

    , , , & The SH-3 and SH-4 antibodies recognize distinct epitopes on CD73 from human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 289, 519–524 (2001).

  11. 11.

    et al. Stage-specific embryonic antigens (SSEA-3 and -4) are epitopes of a unique globo-series ganglioside isolated from human teratocarcinoma cells. EMBO J. 2, 2355–2361 (1983).

  12. 12.

    et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145–1147 (1998).

  13. 13.

    , & Characterization and differentiation of human embryonic stem cells. Cloning Stem Cells 5, 79–88 (2003).

  14. 14.

    et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc. Natl. Acad. Sci. USA 95, 13726–13731 (1998).

  15. 15.

    , , & Stem cell pluripotency and transcription factor Oct4. Cell Res. 12, 321–329 (2002).

  16. 16.

    Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc. Natl. Acad. Sci. USA 78, 7634–7638 (1981).

  17. 17.

    & Establishment in culture of pluripotential cells from mouse embryos. Nature 292, 154–156 (1981).

  18. 18.

    et al. Derivation of embryonic stem-cell lines from human blastocysts. N. Engl. J. Med. 350, 1353–1356 (2004).

  19. 19.

    , , & Telomere length dynamics in telomerase-positive immortal human cell populations. Exp. Cell Res. 239, 370–378 (1998).

  20. 20.

    & Amniotic fluid-derived pluripotential cells: adult and fetal. In Handbook of Stem Cells, Vol. 2. (eds. R. Lanza et al.) 175–180, (Elsevier Academic Press, Amsterdam, 2004).

  21. 21.

    & Integration target site selection for retroviruses and transposable elements. Cell. Mol. Life Sci. 61, 2588–2596 (2004).

  22. 22.

    , & CNS stem cells express a new class of intermediate filament protein. Cell 60, 585–595 (1990).

  23. 23.

    et al. Derivation of midbrain dopamine neurons from human embryonic stem cells. Proc. Natl. Acad. Sci. USA 101, 12543–12548 (2004).

  24. 24.

    , & Heteromultimerization of G-protein-gated inwardly rectifying K+ channel proteins GIRK1 and GIRK2 and their altered expression in weaver brain. J. Neurosci. 16, 7137–7150 (1996).

  25. 25.

    et al. Intrinsic resistance of neural stem cells to toxic metabolites may make them well suited for cell non-autonomous disorders: evidence from a mouse model of Krabbe leukodystrophy. J. Neurochem. 97, 1585–1599 (2006).

  26. 26.

    & The twitcher mouse: a model for Krabbe disease and for experimental therapies. Brain Pathol. 5, 249–258 (1995).

  27. 27.

    & Gene expression in osteoblastic cells. Crit. Rev. Eukaryot. Gene Expr. 1, 85–98 (1991).

  28. 28.

    et al. Inkjet printing for high-throughput cell patterning. Biomaterials 25, 3707–3715 (2004).

  29. 29.

    , , , & Inkjet printing of viable mammalian cells. Biomaterials 26, 93–99 (2005).

  30. 30.

    & Hayflick, his limit, and cellular ageing. Nat. Rev. Mol. Cell Biol. 1, 72–76 (2000).

  31. 31.

    Amniotic fluid cell types and culture. Br. Med. Bull. 39, 348–354 (1983).

  32. 32.

    , , , & The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 335, 88–89 (1988).

  33. 33.

    From white spots to stem cells: the role of the Kit receptor in mammalian development. Trends Genet. 9, 285–290 (1993).

  34. 34.

    & Characterization and culture of human embryonic stem cells. Nat. Biotechnol. 23, 699–708 (2005).

  35. 35.

    , , & Autocrine regulation of neural crest cell development by steel factor. Dev. Biol. 184, 61–69 (1997).

  36. 36.

    & Neural crest stem and progenitor cells. Annu. Rev. Cell Dev. Biol. 22, 267–286 (2006).

  37. 37.

    & GeneChips in regenerative medicine. In Principles of Regenerative Medicine. (eds. A. Atala, R. Lanza, J.A. Thomson & R.M. Nerem) in press (Elsevier, Philadelphia, 2006).

  38. 38.

    Recent developments in tissue engineering and regenerative medicine. Curr. Opin. Pediatr. 18, 167–171 (2006).

  39. 39.

    Regulation of enzymes of the urea cycle and arginine metabolism. Annu. Rev. Nutr. 22, 87–105 (2002).

  40. 40.

    , & Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. J. Exp. Med. 191, 1699–1708 (2000).

  41. 41.

    , , & Osteogenic differentiation of purified, culture-expanded human mesenchymal stem cells in vitro. J. Cell. Biochem. 64, 295–312 (1997).

  42. 42.

    et al. Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279, 1528–1530 (1998).

  43. 43.

    , , & Culturing satellite cells from living single muscle fiber explants. In Vitro Cell. Dev. Biol. Anim. 31, 773–779 (1995).

  44. 44.

    et al. Hepatic maturation in differentiating embryonic stem cells in vitro. FEBS Lett. 497, 15–19 (2001).

  45. 45.

    et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J. Clin. Invest. 109, 1291–1302 (2002).

  46. 46.

    , , & Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 61, 364–370 (2000).

  47. 47.

    , , & Functional significance of cannabinoid-mediated, depolarization-induced suppression of inhibition (DSI) in the hippocampus. J. Neurophysiol. 90, 55–64 (2003).

Download references

Acknowledgements

We acknowledge support from the Joshua Frase Foundation, Fondazione Citta' della Speranza, the Crown Foundation and the March of Dimes. We are grateful to Paola Dal Cin and Mark Pettenati for access to amniocentesis specimens, Sam Deadwyler and Robert Hampson for electrophysiology, and Daragh Conrad and Heather Mertz for the cover image.

Author information

Author notes

    • Paolo De Coppi
    •  & Georg Bartsch Jr

    These authors contributed equally to this work.

Affiliations

  1. Wake Forest Institute for Regenerative Medicine, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157-1094, USA.

    • Paolo De Coppi
    • , Georg Bartsch Jr
    • , M Minhaj Siddiqui
    • , Tao Xu
    • , Cesar C Santos
    • , Laura Perin
    • , James J Yoo
    • , Mark E Furth
    • , Shay Soker
    •  & Anthony Atala
  2. Children's Hospital and Harvard Medical School, 300 Longwood Avenue, Boston, Massachusetts, 02115, USA.

    • Gustavo Mostoslavsky
    • , Angéline C Serre
    •  & Evan Y Snyder

Authors

  1. Search for Paolo De Coppi in:

  2. Search for Georg Bartsch in:

  3. Search for M Minhaj Siddiqui in:

  4. Search for Tao Xu in:

  5. Search for Cesar C Santos in:

  6. Search for Laura Perin in:

  7. Search for Gustavo Mostoslavsky in:

  8. Search for Angéline C Serre in:

  9. Search for Evan Y Snyder in:

  10. Search for James J Yoo in:

  11. Search for Mark E Furth in:

  12. Search for Shay Soker in:

  13. Search for Anthony Atala in:

Contributions

P.D.C., G.B. and M.M.S., cell isolation and in vitro differentiation; T.X. and J.J.Y., in vivo bone engineering; C.C.S. and S.S., neuronal differentiation; L.P., telomere length; G.M. and M.M.S., retroviral marking; A.C.S. and E.Y.S., brain engraftment; S.S. and M.E.F., molecular analysis; A.A., principal investigator.

Competing interests

A.A. assigned to Children's Hospital Boston a patent involved with this technology and Children's Hospital licensed the patent to Plureon, Inc. A.A. serves as a member of the board of directors of Plureon, Inc.

Corresponding author

Correspondence to Anthony Atala.

Supplementary information

PDF files

  1. 1.

    Supplementary Fig. 1

    Marker expression by human AFS cells.

  2. 2.

    Supplementary Fig. 2

    Marker expression by mouse AFS cells.

  3. 3.

    Supplementary Fig. 3

    Osteogenic differentiation of human AFS cells.

  4. 4.

    Supplementary Table 1

    Marker expression of cells from human amniotic fluid.

  5. 5.

    Supplementary Methods

Zip files

  1. 1.

    Supplementary Video

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt1274

Further reading